IL6R and Castleman disease: Notably, a monoclonal antibody that directly blocks IL-6R, tocilizumab, has dramatic effectiveness as a therapy for cytokine storms induced by various conditions, including Castleman’s disease, CAR T-cell-induced cytokine storm, and coronavirus disease 2019 (COVID-19)9,20.